About
A research organisation built for a long horizon.
Circularity Health is at concept stage. We are setting out the questions, the standards and the partnerships we believe longevity research needs — before we build anything that claims to work.
Mission
To extend healthy human life by building rigorous, accessible longevity research.
We are researching the mechanisms of ageing and the technologies that might intervene in them — with the explicit intention that any progress is measured in healthy years, not headlines.
Vision
A world where the extra years science makes possible are years people would want to live.
Longer life without function, dignity or access is not an achievement. We are aiming to hold all three together from the outset.
Values
Four values, applied literally.
Rigour
Pre-registered questions, disclosed methods, and results reported whether or not they flatter us.
Openness
We explain what we are doing and what we do not yet know — including the parts that are uncomfortable.
Human-centred
The point is more healthy years for people, not a technical milestone. Access is part of the design.
Long-term thinking
A twenty-five-year horizon needs institutions that can hold a standard across decades, not a quarter.
Founder
Placeholder[Founder name]
Founder & Chief Executive
[PLACEHOLDER BIO — replace before launch.] A short biography will appear here: background in ageing biology or translational medicine, the institutions and programmes they have worked with, and why they started Circularity Health.
[Second paragraph placeholder.] Keep this to two short paragraphs, written in the founder’s own voice, with no claims about outcomes.
All biographical content is a placeholder pending confirmation. No individual is named as a partner, endorser or investor.
Scientific advisory board
Being assembled.
Ageing biology
To be announced
Clinical translation
To be announced
Bioethics
To be announced
Regulatory affairs
To be announced
Advisory seats are planned. No adviser is currently appointed, and no individual or institution is presented as an endorsement.
Where we plan to build
London and San Francisco, planned.
A two-hub model pairing European clinical and regulatory depth with US computational and engineering capability. Neither facility is operating today.
- London — planned base for clinical partnerships, MHRA engagement and translational research.
- San Francisco — planned base for AI-driven discovery, engineering and FDA-facing programmes.
Planned footprint
StylisedBoth locations are planned. No facility is currently operating.
Next step
Building this carefully, in the open.
We are looking for research partners, clinical collaborators and long-horizon investors who share an interest in doing this rigorously.